Clinical Trials Browser

Phase 2 × Lung Neoplasms × Rituximab × Clear all

NCT00001805 2008-03-04

A Phase II Clinical Trial of Suppression of Human Antimouse Antibody and Human Antitoxin Response to Immunotoxin LMB-1 by Rituximab

Phase 2 Completed

BreastGastrointestinalThoracic

Breast Neoplasms, Colonic Neoplasms, Lung Neoplasms, Pancreatic Neoplasms, Stomach Neoplasms